AKEBIA THERAPEUTICS, INC. Cost of Goods and Services Sold
AKEBIA THERAPEUTICS, INC. (AKBA) reported Cost of Goods and Services Sold of $18.61 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-05.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2020-05-05
- AKEBIA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2020-03-31 was $18.61M, a 15.99% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2019-12-31 was $29.05M.
- AKEBIA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2019-09-30 was $29.16M.
- AKEBIA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2019-06-30 was $28.57M.
- AKEBIA THERAPEUTICS, INC. cost of goods and services sold for fiscal 2019 was $108.94M, a 1642.68% increase from fiscal 2018.
- AKEBIA THERAPEUTICS, INC. cost of goods and services sold for fiscal 2018 was $6.25M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2020-03-31 | $18.61M 10-Q · filed 2020-05-05 | $47.66M derived: sum of 2 quarters · filed 2020-05-05 | $76.82M derived: sum of 3 quarters · filed 2020-05-05 | $105.39M derived: sum of 4 quarters · filed 2020-05-05 |
| 2019-12-31 | $29.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $58.21M derived: sum of 2 quarters · filed 2020-03-12 | $86.78M derived: sum of 3 quarters · filed 2020-03-12 | $108.94M 10-K · filed 2020-03-12 |
| 2019-09-30 | $29.16M 10-Q · filed 2019-11-12 | $57.73M derived: sum of 2 quarters · filed 2019-11-12 | $79.89M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $28.57M 10-Q · filed 2019-08-08 | $50.73M 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $22.16M 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | $6.25M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |